Trial Profile
A Phase 1, Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety and Tolerability of UBX0101 in Moderate to Severe, Painful Osteoarthritis of the Knee
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 May 2020
Price :
$35
*
At a glance
- Drugs UBX-0101 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions; First in man
- Sponsors UNITY Biotechnology
- 21 Mar 2020 Results (n=28) of PK model analysis were presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 24 Oct 2019 According to an UNITY Biotechnology media release, data from this study will be presented at the American College of Rheumatology (ACR) 2019 Annual Meeting.
- 13 Aug 2019 MR-9272615 mentiones moderate-to-severe osteoarthritis, so i have added moderate-to-severe patient segment.